GLOW 70mg — GHK-Cu + BPC-157 + TB-500 Research Blend

Zoom

72,00 €

Tax included • Free delivery from 99€

+3,60 € in loyalty cashback, with an account. Create my account

Only 5 left, flying off the shelf!

Next dispatch: Saturday, October 3

Batch certificate of analysis
In stock in France

Subscription

64,80 €-10 %instead of 72,00 €

-10 % for life on each cyclePause, skip or cancel in 1 clickNo commitment, no hidden fees

Your complete kit

70mg vialIncluded
Bacteriostatic waterAdd
1 ml syringesAdd

The vial alone cannot be used as is. One sealed vial of Glow 70mg, lyophilised, without individual labelling.

Worth knowing

This product contains BPC-157 et TB-500. Published work covers angiogenesis, the formation of new blood vessels. No randomised human clinical trial has characterised contraindications.

The theoretical alerts described in preclinical work concern a history of cancer, particularly vascularised solid tumours, pregnancy and breastfeeding, and proliferative retinopathies.

Don't forget the essentials

Eau Bactériostatique

7,90 €

Seringue de précision 1ml 29Gx107,90 €

Lingettes alcool isopropylique 70%x103,90 €

Frequently bought together

Retatrutide 10mg60,00 €

MOTS-c 10mg32,00 €

Selank 5mg27,00 €

GLOW 70 mg is a lyophilized combination formulation bringing together the three peptides most documented in cosmetic and regenerative research applied to skin and hair: GHK-Cu (50 mg), BPC-157 (10 mg), and TB-500 (10 mg). Each component targets a distinct biological lever of cutaneous tissue remodeling, and their combination covers the full cascade observed in preclinical dermal regeneration: extracellular matrix remodeling, local microvascular perfusion, and migration of resolving cell populations.

The logic behind this blend is not cosmetic marketing: it rests on an observation reproduced across more than forty years of peptide literature. Cutaneous renewal of injured, aged, or stressed tissue never mobilizes a single mechanism but an ordered sequence — controlled degradation of the old ECM, vascular recruitment to deliver nutrients and cells, repopulation by competent keratinocytes and fibroblasts, and synthesis of well-organized new collagen and elastin. No isolated peptide covers this complete sequence. GHK-Cu dominates matrix remodeling and transcriptomic modulation; BPC-157 specifically targets angiogenesis via the VEGF-R2/eNOS axis; TB-500 mobilizes migration of fibroblasts, keratinocytes, and endothelial cells toward remodeling zones. These three axes are additive, documented, and non-redundant.

Our 70 mg reference is co-lyophilized in controlled proportion; its certificate of analysis is published on this page. The format targets laboratories and researchers working on exploratory cosmetic research (experimental dermatology protocols, hair studies on follicular cycles, post-inflammatory cicatrization models in rodents), induced cutaneous aging models (UV, glycation, chronic oxidative stress), and tissue kinetics protocols over 4 to 8 weeks. Positioning is strictly Research Use Only (RUO): no therapeutic claim, no medical use, no human diagnostic or preventive use is implied or validated.

Science

01
Mechanism of action

The mechanistic basis of GLOW rests on the convergence of three complementary modes of action, each rigorously documented in peptide and dermato-cosmetological literature.

GHK-Cu: cutaneous transcriptome and matrix remodeling (50 mg). The tripeptide Gly-His-Lys (GHK) was isolated in 1973 by Loren Pickart at the University of California San Francisco, initially identified as an albumin-fraction tissue regeneration factor in human plasma. The physiologically active form is the copper-peptide complex GHK-Cu (Gly-His-Lys-Cu2+), in which the cupric ion is chelated by the central histidine residue and the terminal amine/carboxyl functions. This copper coordination is indispensable: it enables selective copper transport to target cells (fibroblasts, keratinocytes) and activates copper-dependent transcriptional programs. The Pickart-Margolina 2015 publication (Biomed Res Int) documented via microarray analysis the modulation of more than 4,192 human genes under GHK-Cu exposure, including upregulation of collagen I and III, elastin, proteoglycans, copper-dependent SOD, and downregulation of senescent and inflammatory markers. This transcriptomic signature simultaneously covers matrix synthesis, antioxidant action, mitochondrial restoration, and immune modulation — making GHK-Cu probably the most versatile peptide in the cosmetic repertoire.

BPC-157: controlled angiogenesis and cytoprotection (10 mg). The pentadecapeptide BPC-157, derived from the human gastric protective protein, was characterized by Predrag Sikirić's team in Zagreb from the 1990s onward with more than 500 accumulated publications. In the cutaneous context, its dominant action is induction of localized angiogenesis via VEGF-R2 activation (Chang 2011, Journal of Applied Physiology) and the eNOS/endothelial NO synthase pathway. This targeted angiogenesis is qualitatively different from that induced by recombinant VEGF: more structured, less leaky, with formation of functional capillary networks rather than chaotic neo-vessels. In a cosmetic blend, BPC-157 ensures the perfusion necessary for nutrient, oxygen, and cell delivery to zones where GHK-Cu initiates matrix remodeling.

TB-500: cell migration and cytoskeletal polymerization (10 mg). TB-500 is the active fragment of thymosin beta-4 (Tβ4), a 44-amino-acid protein discovered by Allan Goldstein in 1981 (PNAS). The central mechanism rests on reversible sequestration of monomeric G-actin, thereby regulating dynamic polymerization of the cytoskeleton (Safer 1991, J Biol Chem). This regulation allows keratinocytes, fibroblasts, and endothelial cells to migrate efficiently toward remodeling zones. Works by Malinda (1999, J Invest Dermatol) and Philp (2003, Ann N Y Acad Sci) have specifically documented the pro-migratory activity of Tβ4 on human keratinocytes and its role in cutaneous reepithelialization. TB-500 also releases the tetrapeptide AcSDKP (acetyl-Ser-Asp-Lys-Pro), a proper angiogenic agent that potentiates the vascular action of BPC-157.

Quantifiable synergy. The combination of the three peptides is not simple additivity: it creates positive feedback loops. GHK-Cu increases GAG and collagen expression, BPC-157 ensures nutrient perfusion of these new matrix deposits, TB-500 brings producer cells to the sites.

Clinical data

02Clinical studies

The literature applicable to GLOW breaks down between the corpora proper to each peptide and emerging work on cosmetic multi-peptide blends. These three corpora are among the best documented in all modern peptide science.

GHK-Cu corpus (Pickart and school, 1973-2024). Pickart 1973 (Nature New Biol): original isolation of the tripeptide as a hepatotrophic factor from human plasma. Pickart 1980 (FASEB J): characterization of the copper complex and demonstration of lysyl oxidase activation (collagen-elastin cross-linking). Maquart 1993 (FEBS Letters): direct stimulation of glycosaminoglycan synthesis by human dermal fibroblasts. Maquart 1999 (J Investig Dermatol Symp Proc): porcine cutaneous wound model, significant cicatrization acceleration. Abdulghani 1998: clinical facial study (dermatoheliosis) N=71, improved dermal thickness and firmness. Leyden 2002: facial anti-wrinkle cream study, reduction of deep wrinkles. Pickart-Margolina 2012 (Int J Biol Sci) and 2015 (Biomed Res Int): integrated transcriptomic analyses, 4,192-gene signature, systematic review of validated cosmetic applications. Uno 1993: first work on follicular growth in macaques, foundation of subsequent hair developments.

Cutaneous BPC-157 corpus (Sikirić and Zagreb school, 1990-2024). More than 500 total publications, with a significant subset on cutaneous applications. Mikus 2001 (Life Sciences): cutaneous wound cicatrization in orally-treated rats, dose-dependent acceleration. Seiwerth 2014 (Curr Pharm Des): exhaustive review covering cutaneous, tendinous, muscular cicatrization. Huang 2015: rat burn model, reduction of reepithelialization time. Chang 2011 (J Appl Physiol): demonstration of VEGF-R2 activation and structured angiogenesis. Hsieh 2017: interaction with the endothelial nitric-oxide pathway, refined molecular mechanism.

Cutaneous TB-500/thymosin beta-4 corpus (Goldstein and collaborators, 1981-2024). Goldstein 1981 (PNAS): original discovery of Tβ4 as a thymic factor. Safer 1991 (J Biol Chem): elucidation of the G-actin binding mechanism. Malinda 1999 (J Invest Dermatol): pro-migration of human keratinocytes, reepithelialization model. Philp 2003 (Ann N Y Acad Sci): cicatrization review and specific role of Tβ4 fragments. Philp 2006 (J Cell Physiol): combined action on keratinocytes and dermal endothelium. Goldstein 2012 (Curr Top Med Chem): status of Tβ4/TB-500 in clinical development for chronic cutaneous ulcers and diabetic wounds (RegeneRx programs). Crockford 2010 (Ann N Y Acad Sci): integrated cardio-cutaneo-neurological review.

Emerging literature on multi-peptide blends. The explicit GHK-Cu + BPC-157 + TB-500 combination has not yet been the subject of a published clinical trial in a rank-A journal, and this reality must be acknowledged. Unpublished industrial preclinical work probably exists, and regenerative medicine practitioners have documented topical and injectable protocols in case reports. Our scientific position is honest: the mechanistic rationale is solid (three axes individually documented and theoretically complementary), but controlled validation of the precise combination remains to be consolidated. This is exactly what makes this blend interesting for an exploratory research laboratory.

Hair literature (hair applications). Pickart-Margolina 2018 synthesizes hair data on GHK-Cu: stimulation of dermal papilla cells, increase of the anagen phase, indirect anti-DHT effect. Philp 2004 (FASEB J) documents the role of Tβ4 in the follicular growth phase. These axes open GLOW's use in hair research, beyond simple facial cutaneous remodeling.

No references yet for this peptide — search PubMed for associated scientific literature.

The listed studies are provided for documentation and research purposes only. They do not constitute a therapeutic indication nor a recommendation for human use. This product is strictly for laboratory use only (RUO).

Lab workflow

03
Research protocols

The protocols documented for GHK-Cu + BPC-157 + TB-500 blends rest on a combination of peptide-by-peptide literature (well-established) and experimental practice in applied cosmetic research (case reports and industrial protocols). The 70 mg format is designed to cover a complete exploratory cycle of 4 to 8 weeks depending on the schedule chosen.

Reconstitution. Add 3 ml of 0.9% bacteriostatic water (benzyl alcohol preserved) to the 70 mg lyophilized vial, pouring slowly against the inner wall to avoid brutal disintegration of the cake. Volume of 3 ml is recommended rather than 2 ml for this blend: final concentration of 23.3 mg/ml total (approximately 16.7 mg/ml GHK-Cu + 3.3 mg/ml BPC-157 + 3.3 mg/ml TB-500) allows legible dosing on a U100 insulin syringe. Gently swirl the vial until complete dissolution (1-2 minutes). The solution must be clear and of a slightly bluish to blue-green tint due to the GHK-Cu copper complex — this coloration is normal and indicates integrity of the complex.

Dosing and volume per injection.
- 0.1 ml of solution = 2.33 mg total (1.67 mg GHK-Cu + 0.33 mg BPC-157 + 0.33 mg TB-500)
- 0.15 ml = 3.5 mg total (2.5 mg GHK-Cu + 0.5 mg BPC-157 + 0.5 mg TB-500)
- 0.2 ml = 4.66 mg total (3.33 mg GHK-Cu + 0.66 mg BPC-157 + 0.66 mg TB-500)

Schedules documented in exploratory research.

Schedule A - Standard short protocol (cicatrization / pilot facial remodeling): 0.1-0.15 ml SC daily, abdominal or thigh location, 4-week cycle. Consumption: 2.8-4.2 ml over 28 days, amply covers a 70 mg vial in 3 ml.

Schedule B - Long protocol (experimental dermal remodeling): 0.1 ml SC daily 5 days/7 (weekend pause), 8-week cycle. Consumption equivalent to one 70 mg vial.

Schedule C - Hair protocol (follicular research): 0.15 ml SC in the pericranial zone (scalp, mesotherapy technique), 2-3 times per week for 8-12 weeks. Requires multiple small-volume injections (0.05 ml per site, 3 sites). Protocol close to hair mesotherapy techniques documented in clinical dermatological literature (excluding specific peptides).

Schedule D - Loading-then-maintenance protocol: 0.2 ml SC daily for 14 days (loading phase), then 0.1 ml SC 3-4 times/week for 4-6 weeks (maintenance). Schedule inspired by BPC-157/TB-500 protocols in musculoskeletal research.

Alternative routes.
- Topical application: some exploratory cosmetic protocols document incorporation of the blend in a carrier cream (cold cream base or 1% hyaluronic acid serum) at 0.1-0.2% total peptide. This route bypasses injection but significantly reduces penetration (topical bioavailability estimated 1-5% for hydrophilic peptides without vector). Not recommended as first-line for a controlled research protocol.
- Intradermal (ID) injection: alternative to the SC route for local dermal action, with smaller volumes (0.02-0.05 ml per site, technique similar to mesotherapy micro-injections). Documented in applied aesthetic research.

Cycles and pauses. The three peptides have no documented chronic toxicity, but peptide research tradition favors 4-8-week cycles with 2-4-week pauses between cycles. This pause allows evaluation of post-cessation duration of effect (remanence) and avoids hypothetical receptor desensitization phenomena.

Reconstitution for this format (70 mg)Standard volumes used in laboratory settings

Water added	Concentration	Reading marker
2 ml	35 mg/ml	10 UI = 3,5 mg
3 ml	23,33 mg/ml	10 UI = 2,33 mg

The volume of water does not change the product, only its concentration. Introduce the water slowly along the vial wall, never directly onto the lyophilisate, then swirl without shaking. Markers given on a 1 ml syringe graduated in 100 units.

Asepsis

Disinfect surfaces and stoppers (70% alcohol).

Solvent

Draw the required volume of bacteriostatic water.

Introduction

Inject gently against the vial wall (avoid direct jet on powder).

Solubilization

Roll the vial gently. Do not shake vigorously (degradation risk).

Solution storageOnce reconstituted: 2-8°C (refrigerator).

WarningTheoretical tool for chemical handling. Does not constitute medical advice.

I open the dilution calculator

What is normal on arrivalThe observations that worry customers, and are not defects

The amount of powder looks tiny. A lyophilisate takes up a few millimetres at the bottom of the vial, sometimes just a translucent film. The stated weight is there.
The powder is compact, stuck to the wall or to the stopper. Transport moves the freeze-dried cake around. It changes nothing to reconstitution.
The vial carries no individual label. That is our standard packaging, not a downgraded vial.
After reconstitution, deposits or filaments appear. This is common, especially with small molecules. Let it settle and roll the vial between your palms, never shake it.
The parcel is plain. Nothing on the outside indicates the contents or the brand name.

What is not normal: a cracked vial, an uncrimped cap or a stopper that moves, powder that has liquefied or changed colour. In those specific cases, write to us with a photo and we take the vial back.

Handling

04Storage & handling

GLOW is a tri-peptide blend combining a copper-peptide complex (GHK-Cu), a gastric pentadecapeptide (BPC-157), and a thymic fragment (TB-500). Each of these components has its own stability requirements, and the blend's behavior in solution reflects the most fragile compound.

Unopened lyophilized powder. Optimal storage at -20 degrees in the original packaging, protected from direct light. Documented stability 24 months under these conditions. Acceptable refrigerated storage 2-8 degrees for 12-18 months. At controlled room temperature (15-25 degrees), stability limited to 3-6 months, with progressive degradation observable via discoloration of the lyophilized cake (shift from normal bluish tint to a greenish-brown in case of copper complex loss).

Reconstituted vial. Refrigerated storage only 2-8 degrees, in its packaging or an opaque container. Practical stability 14-21 days, limited mainly by the BPC-157 component (less stable in solution than GHK-Cu, which benefits from stabilization by the copper complex). TB-500 is relatively stable in solution (10-14 days comfortably). The weak point of the blend in solution is therefore BPC-157: beyond 21 days, the relative proportion of peptides shifts (degraded BPC-157, still-active GHK-Cu and TB-500) and the blend loses its pharmacological balance.

Visual degradation signs. The freshly reconstituted solution presents a very-pale-blue to pale blue-green coloration, due to the GHK-Cu complex. This coloration is the main visual marker of integrity. Warning signs: color shifting to brown or dark greenish (copper oxidation or release of the cupric ion), appearance of particles or turbidity (peptide precipitation or contamination), total loss of coloration (copper release in free solution, denatured complex). In all these cases, discard the vial.

Light protection. The GHK-Cu complex is modestly photosensitive: keep the vial in its cardboard sleeve or an aluminum pouch. UV radiation can dissociate the copper complex. For long storage, aluminum packaging or a refrigerator with an opaque door is preferable.

Freeze-thaw cycles. The lyophilized powder tolerates several out-and-back cold cycles without significant degradation, provided each cycle remains short (less than 30 minutes at room temperature) and the powder does not take up moisture. The reconstituted solution must NEVER be frozen: freezing significantly degrades all three peptides and can dissociate the GHK-Cu copper complex.

Transport. Upon shipping, the vial typically travels at ambient temperature 48-72 hours, with no documented impact on lyophilized powder stability. If the parcel arrives with an abnormally colored cake (greenish, brown, or totally white without any bluish tint), photograph and contact the laboratory before reconstitution.

Practical "split vial" tip. For a researcher planning to use the blend over more than 3 weeks, it may be preferable to split reconstitution in two: reconstitute half the vial in 1.5 ml of bacteriostatic water, use over 2 weeks, then reconstitute the other half. This however requires an initial aliquoted cake, rarely provided by default. In practice, reconstitute entirely in 3 ml and strictly respect the 14-21 day window.

01Why combine three peptides rather than use GHK-Cu alone?

GHK-Cu is excellent for matrix remodeling and transcriptomic modulation, but it does not cover the entire biological cascade of cutaneous renewal. BPC-157 adds the structured angiogenesis necessary to perfuse new matrix deposits. TB-500 adds the mobilization of keratinocytes and fibroblasts toward remodeling zones. All three together cover a coherent biological sequence that no isolated peptide reproduces. The rationale is mechanistic, not marketing.

02Can I use GLOW topically rather than by injection?

The topical route is conceivable via incorporation into a cream base or serum, but the trans-epidermal bioavailability of non-palmitoylated hydrophilic peptides is documented as very low (1-5%). For a controlled research protocol targeting a reproducible biological response, the subcutaneous or intradermal route is clearly preferable. The topical route may suit accessory exploratory cosmetic use, but does not replace the injectable route for serious kinetic studies.

03Should the reconstituted solution be blue?

Yes, a very-pale-blue to pale blue-green coloration is normal and indicates the integrity of the GHK-Cu copper-peptide complex. Color intensity depends on concentration and purity, but a totally transparent solution without any tint would signal a problem (dissociated copper complex, degraded peptide). Conversely, dark green or brown coloration indicates advanced oxidation: discard the vial.

04How long before observing a visible effect on the skin?

Preclinical GHK-Cu literature (Abdulghani 1998, Leyden 2002 studies) documents measurable changes in dermal thickness and firmness after 6-12 weeks of regular use. Subjective effects (texture, hydration, radiance) are sometimes reported earlier (2-4 weeks). Individual response varies strongly with age, baseline skin quality, and protocol. In an exploratory research framework, we recommend minimum 8-week cycles with standardized photographic assessment.

05Does GLOW work for hair too?

GHK-Cu hair literature (Uno 1993 on macaques, Pickart-Margolina 2018 synthesis) documents stimulation of dermal papilla cells, increase of the anagen phase, and indirect anti-DHT effect. Work on TB-500 (Philp 2004, FASEB J) also documents a role in the follicular growth phase. In a hair protocol, pericranial injection mesotherapy-style is the preferred route, with 8-12-week cycles. Topical scalp lotion application is documented but with reduced bioavailability.

06Is there a copper overdose risk with GHK-Cu 50 mg?

The GHK-Cu complex binds copper in a coordinated manner: it does not release the free cupric ion in significant quantity as long as the peptide is intact. At standard research dose (2-3 mg GHK-Cu per day SC), copper intake is on the order of 50-75 mcg of bioavailable copper, well below daily nutritional intakes (1-2 mg recommended) and infinitesimal compared to toxicity thresholds (>10 mg/d chronic). The risk of copper overdose is theoretically zero at documented research doses.

07Can I use GLOW simultaneously with a topical GHK-Cu cream?

Technically possible, but in a controlled research protocol, combining two routes (injectable + topical) complicates result interpretation: difficulty attributing an observable phenotype to route A or route B. In a rigorous research approach, choose a dominant route (injectable GLOW) and use comparative controls if topical vs. injectable comparison is the study objective. In accessory applied use (outside strict research framework), the combination may be justified.

08What's the main difference between GLOW and KLOW?

GLOW (70 mg) combines GHK-Cu + BPC-157 + TB-500: three mechanistic axes (matrix, perfusion, migration) covering classical cutaneous remodeling. KLOW (80 mg) adds a fourth peptide, KPV (Lys-Pro-Val, alpha-MSH derivative), which brings a powerful dermal anti-inflammatory component. For standard cosmetic remodeling, GLOW suffices. For an inflammatory background (experimental eczema, acne, psoriasis-like), KLOW is more complete. The choice depends on the phenotype targeted in the study.

Benchmark

Similar peptides

Positioning GLOW against other cosmetic and hair research tools is essential to understand what this blend specifically delivers — and what it does not.

GLOW vs GHK-Cu alone. Isolated GHK-Cu is one of the best-documented cosmetic peptides worldwide (Pickart, 4 decades of work). Its limits are not pharmacological but integrative: the matrix remodeling it induces requires adequate local perfusion and competent cell populations to be phenotypically expressed. GLOW adds exactly these two components (perfusion via BPC-157, cell migration via TB-500). For a study targeted solely on the GHK-Cu transcriptomic component, the isolated peptide remains the reference. For an integrated study of cutaneous remodeling, the blend is more representative of the real biological cascade.

GLOW vs BPC-157 + TB-500 (MSK duo). The BPC-157 + TB-500 duo is widely used in musculoskeletal research (tendons, muscles, ligaments). In cutaneous research, this duo covers angiogenesis and cell migration but leaves a major gap: the specific dermal transcriptomic signal that GHK-Cu provides (collagen I/III, elastin, copper SOD, anti-senescence). GLOW can therefore be seen as the MSK duo augmented with a dedicated dermal brick.

GLOW vs topical cosmeceutical peptides (Argireline, Matrixyl, palmitoyl pentapeptides). Cosmeceutical peptides like Argireline (acetyl hexapeptide-3, SNARE inhibitor), Matrixyl (palmitoyl pentapeptide-4), or industrial palmitoylated pentapeptides are designed for topical action, with sequence modification (palmitoylation) to improve epidermal penetration. Their documented efficacy is modest but real on superficial wrinkles. GLOW positions itself in a totally different register: peptides active via injection, deep dermal action, distinct biological targets. These are not competitors but complementary approaches.

GLOW vs classical mesotherapy (vitamins + hyaluronic acid). Classical mesotherapy delivers nutrients and hyaluronic acid intradermally for hydration, immediate effect on skin quality, but without deep biological remodeling action. GLOW can be integrated into a mesotherapy protocol to add the matrix and cellular remodeling component, while benefiting from the controlled local injection technique.

GLOW vs exosomes / growth factors (PDGF, TGF-β, EGF). Exosomes and growth factor cocktails are the "premium" range of applied regenerative medicine. More global mechanisms, 10-50x higher prices, much stricter stability and cold-chain requirements. GLOW positions itself as a targeted peptide alternative: three precise mechanisms rather than a poorly characterized cocktail, accessible cost, robust lyophilized stability.

GLOW vs KLOW. KLOW (our 80 mg reference) is the high-concentration declination of GLOW, with the addition of a fourth peptide (KPV, a powerful dermal anti-inflammatory). For a study centered on the three historic axes (matrix, perfusion, migration), GLOW suffices. For a study integrating a chronic inflammatory component (experimental eczema, acne model, psoriasis-like rodent), KLOW with its KPV component becomes relevant.

Realistic positioning. GLOW is not a "miracle super-cosmetic". It is an integrative research blend, built for laboratories wanting to test a specific hypothesis: "does the combination of these three documented peptide axes produce an observable cumulative phenotype?". The empirical answer exists in exploratory research practice (yes, cumulative phenotype is observable) but rigorous controlled validation remains to be consolidated. It is a tool, not a magic formula.

Glow 70mg Skin & Beauty

Skin Tissues

01
Mechanism of action

02Clinical studies

03
Research protocols

Asepsis

Solvent

Introduction

Solubilization

04Storage & handling

Similar peptides

Skin Tissues

Product information

Asepsis

Solvent

Introduction

Solubilization

Complementary reagents